Ulugol, AhmetOltulu, CagatayGunduz, OzgurCitak, CihadCarrara, RobertoShaqaqi, Mohammad RezaMansilla Sanchez, Alicia2024-06-122024-06-1220120091-3057https://doi.org/10.1016/j.pbb.2012.05.006https://hdl.handle.net/20.500.14551/2045114th World Congress on Pain -- AUG 27-31, 2012 -- Milan, ITALYThe role of 5-HT7 receptors in the nociceptive processing received most attention during the last few years. The involvement of 5-HT7 receptors in nerve injury-induced neuropathic pain states have been reported only recently; however, there are no reports on its contribution in diabetic neuropathic pain. We therefore planned to investigate the effect of 5-HT7 receptor activation on the changes of nociceptive threshold in diabetic mice. Diabetes was induced by a single intraperitoneal injection of streptozocin (150 mg/kg, i.p.). The nociceptive responses in normal and diabetic animals were tested in the hot-plate and tail-flick assays. Both hot-plate and tail-flick latencies significantly shortened at 1-3/4 weeks (thermal hyperalgesia) and prolonged at 6-7 weeks (thermal hypoalgesia) after streptozocin administration. At the dose of 10 mg/kg, systemic injections of AS-19, a selective 5-HT7 receptor agonist, reduced thermal hyperalgesia at early stage of diabetes, but did not influence thermal hypoalgesia at late stage. Co-administration of SB-258719, a selective 5-HT7 receptor antagonist, at a dose that had no effect on its own (10 mg/kg), reversed the anti-hyperalgesic effect of AS-19. Our results indicate that systemic administration of 5-HT7 receptor agonists may have clinical utility in treating diabetic neuropathic pain. (C) 2012 Elsevier Inc. All rights reserved.en10.1016/j.pbb.2012.05.006info:eu-repo/semantics/closedAccessDiabetesThermal HyperalgesiaThermal HypoalgesiaSerotonin5-HT7 ReceptorsDescending Serotonergic PathwaysSpinal 5-Ht7Tactile AllodyniaNeuropathic PainModelAntinociceptionPathogenesisRatsConference Object1022344348Q2WOS:0003067760000222-s2.0-8486181548222609798Q1